The purpose of this study is to see if treatment with the drugs docetaxel and OGX-427 is more effective for prolonging survival than docetaxel alone in patients with urothelial cancers (those of the bladder, urethra, ureter, and renal pelvis) that have returned or persisted despite prior treatment with cisplatin or carboplatin. Docetaxel is an approved anticancer drug that is widely used to treat a variety of cancers, including advanced bladder cancer.
OGX-427 is an investigational drug that works by inhibiting the activity of a protein called Hsp27. This protein is produced in large quantities by cancer cells and protects them from the lethal effects of anticancer treatments. It is hoped that OGX-427 will make the cancer cells more susceptible to docetaxel and make docetaxel work better.
Patients will be randomly assigned to receive docetaxel plus OGX-427 or docetaxel alone. Both drugs are given intravenously (by vein).